Standard BioTools (LAB) Set to Report Earnings Soon

Standard BioTools (NASDAQ:LAB) is expected to announce its quarterly earnings after the market closes on Wednesday, February 26. Analysts predict that the company will report earnings of ($0.03) per share and revenue of $43.03 million for the quarter. For those interested in following up on this announcement, registration for the earnings conference call can be done using this link.

Stock Performance of Standard BioTools

On Wednesday, shares of Standard BioTools opened at $1.40. The stock has a fifty-day moving average of $1.73 and a two-hundred-day moving average of $1.82. Over the past year, the stock has reached a low of $1.17 and a high of $3.04. Currently, the company has a market capitalization of approximately $521.16 million, a price-to-earnings ratio of -1.97, and a beta of 1.57.

Analyst Insights

In recent updates, TD Cowen has lowered its price target for Standard BioTools from $2.75 to $2.50. Despite this adjustment, the firm maintains a "buy" rating on the stock.

Understanding Standard BioTools

Standard BioTools Inc specializes in providing a variety of instruments, consumables, reagents, and software services aimed at supporting researchers and clinical laboratories across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. The company's operations are divided into two main segments: Proteomics and Genomics. Among its offerings are advanced analytical systems such as the CyTOF XT System, which utilizes high-parameter single-cell analysis with antibodies linked to metal isotopes, and the Hyperion XTi imaging system, dedicated to spatial biology.

Standard, BioTools, Earnings